122 results on '"Silva, Ariosto S."'
Search Results
2. Classifying the evolutionary and ecological features of neoplasms
3. Abstract B019: The bone microenvironment's impact on the heterogeneity of resistance to proteasome inhibitors in multiple myeloma
4. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms
5. Figure S7 Part 2 from CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma
6. CK1δ/CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma
7. Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All
8. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
9. Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma
10. Supplementary Video 1 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
11. Data from The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion
12. Data from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
13. Supplementary Figure 4 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
14. Supplementary Information from The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion
15. Supplementary Methods from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
16. Supplementary Figure 5 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
17. Data from Adaptive Therapy
18. Supplementary Figure Legend from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
19. Supplementary Figure 1 from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
20. Supplementary Figures 1-4, Methods, Tables 1-3 from Evolution of Tumor Invasiveness: The Adaptive Tumor Microenvironment Landscape Model
21. Supplementary Table 1 from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
22. Supplementary Figure 2 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
23. Supplementary Figure 7 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
24. Supplementary Figure 3 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
25. Data from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
26. Data from Evolution of Tumor Invasiveness: The Adaptive Tumor Microenvironment Landscape Model
27. Free Article from Adaptive Therapy
28. Supplementary Figure 1 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
29. Supplementary Figure 6 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
30. Replicative Instability Drives Cancer Progression
31. CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation
32. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
33. Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma
34. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma
35. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
36. An Advanced Framework for Time-lapse Microscopy Image Analysis
37. A pharmacodynamic model of clinical synergy in multiple myeloma
38. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
39. A theoretical quantitative model for evolution of cancer chemotherapy resistance
40. An Evolutionary Approach for Personalized Therapy in Multiple Myeloma
41. A Preclinical Assay for Chemosensitivity in Multiple Myeloma
42. Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
43. Abstract 3194: Reverse engineering the interplay between multiple myeloma and microenvironment
44. Evolution of Tumor Invasiveness: The Adaptive Tumor Microenvironment Landscape Model
45. Adaptation to Survival in Germinal Center Is the Initial Step in Onset of Indolent Stage of Multiple Myeloma
46. Abstract 21: Understanding the progression and chemotherapy resistance of Multiple Myeloma in the bone marrow through evolutionary computational models and in vitro experiments
47. Abstract 437: A putative role of hypoxia in development of de novo chemoresistance
48. A quantitative theoretical model for the development of malignancy in ductal carcinoma in situ
49. A theoretical quantitative model for evolution of cancer chemotherapy resistance
50. Adaptive Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.